Skip to main content
. 2021 Jan 11;5:PO.20.00265. doi: 10.1200/PO.20.00265

FIG 1.

FIG 1.

Enrichment for oncogene fusions in KRASWT pancreatic adenocarcinoma. Targetable fusions were identified in 4 of 13 KRASWT patients with no alternative driver oncogenes identified. Additionally, a FGFR2 rearrangement was identified that was predicted to be activating.